Dr. Rami Komrokji discussed MDS and secondary AML in 2025, noting 50,000 new MDS cases yearly and 1/3 progressing to AML. Key factors include CHIP and CCUS. Luspatercept is standard for RS+ MDS; telestat for lower-risk. Transplant is the only cure for high-risk MDS; hypomethylating agents offer limited benefit.